Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-16T03:45:00.010Z Has data issue: false hasContentIssue false
  • English
  • Français

The Genetics of Schizophrenia Converge Upon the NMDA Glutamate Receptor

Published online by Cambridge University Press:  07 November 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Extract

Recent research shows that single genes do not cause schizophrenia, but that multiple “susceptibility” genes each provide a genetic “bias” towards schizophrenia. Each susceptibility gene codes for a subtle molecular abnormality that hypothetically causes inefficient information processing in brain circuits that mediate the symptoms of this disorder. It is therefore not surprising that many of the susceptibility genes that have been identified for schizophrenia are known to regulate neuronal connectivity, synaptogenesis, and N-methyl-D-aspartate (NMDA) glutamate receptor functions. This includes genes for brain-derived neurotrophic factor (BDNF), dysbindin, also known as dystrobrevin-binding protein 1, neuregulin, disrupted in schizophrenia-1 (DISC-1), D-amino acid oxidase activator (DAOA), and regulator of G-protein signaling (RGS4). Hypothetically, converging molecular abnormalities expressed by defective versions of these genes could cause dysregulation of NMDA receptors and NMDA synapses, leading to vulnerability for schizophrenia due to inefficient information processing at glutamate synapses.

Type
Trends in Psychopharmacology
Information
CNS Spectrums , Volume 12 , Issue 8 , August 2007 , pp. 583 - 588
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Stephan, KE, Baldeweg, T, Friston, KJ. Synaptic plasticity and disconnection in schizophrenia. Biol Psychiatry. 2006;59:929–939.CrossRefGoogle Scholar
2.Straub, RE, Weinberger, DR. Schizophrenia genes: famine to feast. Biol Psychiatry. 2006;60:81–83.CrossRefGoogle ScholarPubMed
3.Ishizuka, K, Paek, M, Kamiya, A, Sawa, A. A review of Disrupted-In-Schizophrenia-1 (DISCI): neurodevelopment, cognition, and mental conditions. Biol Psychiatry. 2006;59:1189–1197.CrossRefGoogle Scholar
4.Liu, YL, Fann, CS, Liu, CM, et al.A single nucleotide polymorphism fine mapping study of chromosome 1q42.1 reveals the vulnerability genes for schizophrenia, GNPAT and DISC1: association with impairment of sustained attention. Biol Psychiatry. 2006;60:554–562.CrossRefGoogle ScholarPubMed
5.Cannon, TD, Hennah, W, vanErp, TGM, et al.Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiatry. 2005;62:1205–1213.CrossRefGoogle ScholarPubMed
6.Porteous, DJ, Thomson, P, Brandon, NJ, Millar, JK. The genetics and biology of Disci – an emerging role in psychosis and cognition. Biol Psychiatry. 2006;60:123–131.CrossRefGoogle Scholar
7.Fanous, AH, van den Oord, EJ, Riley, BP, et al.Relationship between a high-risk haplotype in the DTNBP1 (Dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry. 2005;162:1824–1832.CrossRefGoogle ScholarPubMed
8.Green, EK, Raybould, R, Macgregor, S, et al.Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry. 2005;62:642–648.CrossRefGoogle ScholarPubMed
9.Harrison, PJ, Law, AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60;132–160.CrossRefGoogle ScholarPubMed
10.Walss-Bass, C, Liu, W, Lew, DF, et al.A novel missense mutation in the transmembrane domain of neuregulin 1 is associated with schizophrenia. Biol Psychiatry. 2006;60:548–553.CrossRefGoogle ScholarPubMed
11.Goldberg, TE, Straub, RE, Callicott, JH, et al.The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology. 2006;31:2022–2032.CrossRefGoogle ScholarPubMed
12.Detera-Wadleigh, SD, McMahon, FJ. G72/G30 in schizophrenia and bipolar disorder: review and meta analysis. Biol Psychiatry. 2006;60:106–114.CrossRefGoogle ScholarPubMed
13.Williams, NM, Green, EK, Macgregor, S. Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. Arch Gen Psychiatry. 2006;63:366–373.CrossRefGoogle Scholar
14.Ho, BC, Milev, P, O'Leary, DS, Librant, A, Andreasen, NC, Wassink, TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry. 2006;63:731–740.CrossRefGoogle ScholarPubMed
15.Levitt, P, Ebert, P, Mirnics, K, Nimgaonkar, VL, Lewis, DA. Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol Psychiatry. 2006;60:534–537.CrossRefGoogle ScholarPubMed
16.Stahl, SM. Essential Psychopharmacology 3rd ed. New York, NY: Cambridge University Press: In press.Google Scholar
17.Stahl, SM. Beyond the dopamine hypothesis to the NMDA glutamate hypofunction hypothesis of schizophrenia. CNS Spectr. 2007;12:265–268.CrossRefGoogle Scholar
18.Stahl, SM. Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr. 2007;12:423–427.CrossRefGoogle ScholarPubMed